Yes, the FVA measure will be publicly reported for the Medicaid product line for HEDIS 2015.
FAQ Directory
Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can ask a question through My NCQA.
Filter Results
-
Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
-
Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
-
Print
Print this page.
Print this page.
10.15.2014 Flu Vaccinations for Adults Ages 18-64 Will NCQA publicly report the Flu Vaccinations for Adults Ages 18–64 (FVA) measure for the Medicaid product line for HEDIS 2015?
10.15.2014 Relative Resource Use for People With Asthma Should the same change be made to the RAS measure that is also made to step 2 in the Event/Diagnosis section of the ASM, MMA and AMR measures in the HEDIS 2015 Volume 2: Technical Update?
Yes. In the Eligible Population section, replace the text in step 2 with the following: A member identified as having persistent asthma because of at least four asthma medication dispensing events, where leukotriene modifiers or antibody inhibitors were the sole asthma medication dispensed in that year, must also have at least one diagnosis of asthma (Asthma Value Set), in any setting, in the same year as the leukotriene modifier or antibody inhibitor (i.e., the measurement year or the year prior to the measurement year).
This applies to the following Programs and Years:
HEDIS 201510.15.2014 Osteoporosis Management in Women (OMW) The OMW measure’s Osteoporosis Medications Value Set varies from HEDIS. HEDIS includes the HCPCS code J1000; the P4P measure does not include the code. Which value set should we use for the MY 2014 P4P OMW measure?
The HCPCS code J1000 was deleted from the Osteoporosis Medications Value Set (refer to the HEDIS Volume 2 Technical Update memo released October 1, 2014, at www.ncqa.org). The update aligns the HEDIS OMW value sets with the September release of the P4P OMW value sets. We included these updates in the September release of MY 2014 P4P to reduce the edits that P4P organizations must apply with the December release.
This applies to the following Programs and Years:
IHA P4P
10.15.2014
Chlamydia Screening in Women (CHL) There is a discrepancy in the Sexual Activity Value Set between HEDIS 2015, released July 1, 2014, and the MY 2014 P4P Manual released September 2, 2014. The codes appear to relate to a change in the HEDIS value sets (page 89 of the HEDIS 2015 Technical Specifications manual):
• Revised value sets used for event/diagnosis criteria to ensure that supplemental data (e.g., LOINC codes) are not used to identify the denominator. Deleted Pregnancy Tests Value Set and Chlamydia Tests Value Set from the event/diagnosis criteria and added appropriate (e.g., CPT, UB Revenue) codes from these value sets to the Sexual Activity Value Set.
The September 2 release of MY 2014 P4P Manual for measure CHL states that there are no modifications from HEDIS. The following codes are in the HEDIS “Sexual Activity Value Set” and are not in the IHA P4P “Sexual Activity Value Set”:
• CPT codes: 81025, 84702, 84703.
• UBREV code 0925.
P4P also includes the Pregnancy Tests Value Set in the denominator; HEDIS 2015 removed this value set and uses it only in the optional exclusions.
You are correct: The draft P4P manual states that there are no modifications from HEDIS. The differences you see are the result of anticipated P4P changes and updates to the Volume 2 CHL measure, per the HEDIS 2015 Volume 2 Technical Update released on October 1, 2014, at www.ncqa.org.
The HEDIS technical update changes aligns the HEDIS CHL measure specifications and value sets with the September release of the P4P CHL measure and value sets. We included these updates in the September release of MY 2014 P4P to reduce the edits that P4P organizations must apply with the December release.
This applies to the following Programs and Years:
IHA P4P10.15.2014 Evidence Based Cervical Cancer Screening (ECS) The wording and example for the cervical cytology and HPV co-test date range do not match. The example (pages 100–101 of the MY 2014 P4P manual) states, “…if the service date for cervical cytology was December 1 of the measurement year, then the HPV test must include a service date on or between December 1 and December 5 of the measurement year.” If the date range can be four days prior to or four days after, the example should read, “…if the service date for cervical cytology was December 1 of the measurement year, then the HPV test must include a service date on or between November 27 and December 5 of the measurement year.”
Your example is correct. We will amend the example in the specifications for the final release of the P4P manual on December 1, 2014.
For P4P reporting, the cervical cytology and HPV test dates must be four days or fewer apart during the measurement year or the four years prior to the measurement year. We do not specify that the date of the HPV test must be after the cervical cytology test; if cervical cytology is four days or less after an HPV test, it is acceptable.
This applies to the following Programs and Years:
IHA P4P10.15.2014 Diabetes Care (CDC) In the CDC measure (page 64 of the P4P manual), the ED Value Set was added to the “Event/diagnosis” section’s two-visit category. The ED Value Set is also listed for the single-visit category. The logic for identifying members with diabetes for CBPH (page 48 of the P4P manual) does not list a single ED visit as a way to identify a member with diabetes. Should the logic be the same in CDC and CPBH? If so, which is correct?
The logic for identifying a member with diabetes should be the same in CDC and CBPH: At least two ED visits are needed. The bullet on page 64 of the P4P manual was inadvertently placed in the “Event/diagnosis” section. The specification should read:
Claim/encounter data. Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years):
· At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set) or nonacute inpatient encounters (Nonacute Inpatient Value Set) on different dates of service, with a diagnosis of diabetes (Diabetes Value Set). Visit type need not be the same for the two visits.
· At least one acute inpatient encounter (Acute Inpatient Value Set) with a diagnosis of diabetes (Diabetes Value Set).
This change will be reflected in the December release of the MY 2014 P4P Manual.
This applies to the following Programs and Years:
IHA P4P10.15.2014 Clarifying text in UM 6 standard description Must the organization consult with the treating practitioner for every UM decision?
10.15.2014 NA for certification program Does WHP 13, Element E (which requires annual measurement of the effectiveness of two actions addressing improvement opportunities) apply to organizations previously certified in health appraisals or self-management tools under the HIP Standards and Guidelines?
10.15.2014
Annual Monitoring for Patients on Persistent Medications (MPM) The measure updates on page 43 of the MY 2014 P4P manual state that the numerator specifications for ACE/ARB, digoxin and diuretic rates no longer allow a blood urea nitrogen therapeutic monitoring test to count as evidence of annual monitoring.
On page 45, numerator specifications for ACE/ARB state, “At least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year.”
Numerator specifications for digoxin state, “At least one serum potassium, at least one serum creatinine and at least one serum digoxin, and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year.”
Numerator specifications no longer allow a blood urea nitrogen test. Incorrect references to blood urea nitrogen therapeutic monitoring were inadvertently left in the P4P MPM measure specifications and should be removed. This update will be made in the December release of the MY 2014 P4P manual.
This applies to the following Programs and Years:
IHA P4P10.15.2014 Documentation requirements for Medicaid, Medicare and Marketplace product lines Under the 2015 Health Plan Standards and Guidelines, if an organization is bringing through its Medicare, Medicaid or Marketplace product line, what are the documentation expectations for the look-back period?
For certain elements with frequency or analysis requirements, (i.e., MEM 1 Element G; MEM 2 Element C; MEM 4 Element C; MEM 5 Element C; MEM 5 Element D; MEM 7 Element C, factors 3 and 5) the documentation requirement will be limited to a documented process for the Medicare, Medicaid and Marketplace product lines.
This applies to the following Programs and Years:
9.15.2014 Policies and Procedures: Accreditation status and Evaluation Option selection If a Marketplace product line is added to an existing product line through the automatic accreditation add-on process, when the Marketplace product line comes through again, what evaluation option will it be reviewed under, and what status will be available?
An NCQA-Accredited organization that received automatic accreditation via the Marketplace Add-On process may have the Marketplace product line reviewed against the First or Renewal Evaluation Option at the time of its Renewal Survey.
The organization must submit separate Survey Tools for an option other than a Renewal Survey.
The available accreditation statuses, elements reviewed and look-back periods are specified in the standards and guidelines for the selected Evaluation Option.
For First and Renewal Surveys, the accredited status is valid for up to 36 months.
This applies to the following Programs and Years:
9.15.2014 Comprehensive Diabetes Care If a member is numerator negative for at least one indicator in the CDC measure, when may the optional exclusions be applied?
The optional exclusion criteria may be applied only if the member did not have a diagnosis of diabetes during the measurement year or the year prior to the measurement year. If the member was included in the measure based on claim or encounter data, as described in the event/diagnosis criteria, the optional exclusions do not apply because the member had a diagnosis of diabetes. If the member was included in the measure based on pharmacy data alone, the member may meet criteria for an optional exclusion if no diagnosis of diabetes was found in claim or encounter data or in the medical record.
For example, if a member was included in the measure based on pharmacy data but had a visit with a diagnosis of diabetes, the member does not meet optional exclusion criteria.
If a member was included in the measure based on pharmacy data alone and there was no claim or encounter with a diagnosis of diabetes, but medical record documentation indicated the member is a diabetic, the member does not meet optional exclusion criteria.
If a member was included in the measure based on pharmacy data alone and there was no claim or encounter with a diagnosis of diabetes and no evidence of diabetes in the medical record being reviewed, the member may meet optional exclusion criteria if there was a diagnosis of polycystic ovaries any time during the member’s history through December 31 of the measurement year, or a diagnosis of gestational diabetes or steroid-induced diabetes during the measurement year or the year prior to the measurement year.
